Pharmaceuticals Philippines

Philippines Non-Hormonal Menopause Drugs Market Analysis, 2024–2034

Updated Reviewed by Chandani Patel

Philippines Non-Hormonal Menopause Drugs Market Industry Trends and Forecast to 2034: Segmented by (Drug Class, Indication, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

Philippines · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $5.0 Mn Placeholder estimate
Estimate 2025 $5.8 Mn 0.2% of the global market
Projected 2034 $22.6 Mn 289.2% Adds $16.8 Mn over 9 forecast years
CAGR 2025–2034 16.3% Faster than 79% of 180 Pharmaceuticals markets here
Key players 4
  • Philippines is 0.23% of the global market.
  • In APAC, the largest is China at $188.3 Mn.
  • Fastest growing: India at 19.3% a year.
  • Philippines ranks 6th of 10 by size in APAC.

Market size projection

Philippines

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$16.8 Mn total, 2026–2034

Year-by-year market size, 2024–2034
Non-Hormonal Menopause Drugs Market market size by year, Philippines
YearMarket sizeChange that yearSince 2025
2024 (estimate) $5.0 Mn — —
2025 (base) $5.8 Mn +$0.8 Mn —
2026 (forecast) $6.8 Mn +$0.9 Mn +16.3%
2027 (forecast) $7.9 Mn +$1.1 Mn +35.3%
2028 (forecast) $9.1 Mn +$1.3 Mn +57.3%
2029 (forecast) $10.6 Mn +$1.5 Mn +82.9%
2030 (forecast) $12.4 Mn +$1.7 Mn +112.8%
2031 (forecast) $14.4 Mn +$2.0 Mn +147.4%
2032 (forecast) $16.7 Mn +$2.3 Mn +187.8%
2033 (forecast) $19.5 Mn +$2.7 Mn +234.7%
2034 (forecast) $22.6 Mn +$3.2 Mn +289.2%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Report snapshot

Philippines Non-Hormonal Menopause Drugs Market Analysis at a glance
Market size, 2025$5.8 Mn placeholder estimate
Forecast, 2034$22.6 Mn placeholder estimate
Growth (CAGR), 2025–203416.3% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
SegmentsDrug class, indication and end user (see all)
Key playersAstellas Pharma Inc., Bayer AG, Pfizer Inc., Noven Pharmaceuticals (see all)
Regulator in the PhilippinesFDA PhilippinesSource: Food and Drug Administration Philippines. Checked 14 Nov 2026.
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The Philippines Non-Hormonal Menopause Drugs Market Analysis Executive Summary

Non-hormonal menopause drugs treat hot flashes and night sweats without estrogen, for women who cannot or prefer not to use hormone therapy.

Key segments of the non-Hormonal Menopause Drugs market include drug class (NK3 Receptor Antagonists, SSRIs and SNRIs and Gabapentinoids) and indication (Hot Flashes and Sleep Disturbance).

Bar chart: Philippines Non-Hormonal Menopause Drugs market size, 2024–2034, placeholder estimates. $5.0 Mn in 2024, $5.8 Mn in 2025 and $22.6 Mn in 2034, 16.3% CAGR.
Philippines Non-Hormonal Menopause Drugs market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

Philippines Non-Hormonal Menopause Drugs Market Dynamics

Market Growth Drivers

Greater awareness of women's health needs, more funding for female-focused research, later pregnancies and an ageing female population are driving the non-Hormonal Menopause Drugs market. New products designed around women's biology and digital care are improving access.

Opportunity

Femtech, personalised care and new treatments for under-served conditions open strong growth for the non-Hormonal Menopause Drugs market, especially as employers and payers add women's health benefits.

Market Restraints

Under-diagnosis, stigma around some conditions, limited insurance coverage and a long history of under-research in women's health hold back the non-Hormonal Menopause Drugs market.

Competitive Landscape for Non-Hormonal Menopause Drugs Market in Philippines

The non-Hormonal Menopause Drugs market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for Non-Hormonal Menopause Drugs Market in Philippines

Non-Hormonal Menopause Drugs in the Philippines: rules and payment

Drug products need registration with the Food and Drug Administration of the Philippines (FDA).⁠[1] PhilHealth is the national health insurer, and the Universal Health Care Act of 2019 makes every Filipino a member.⁠[2]

[1] Food and Drug Administration Philippines. Checked 14 Nov 2026.

[2] PhilHealth. Checked 14 Nov 2026.

Policy changes and Reimbursement scenario

Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for non-Hormonal Menopause Drugs. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in Philippines.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Non-Hormonal Menopause Drugs right now, from free public sources.

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Non-Hormonal Menopause Drugs in context

The Philippines compared

  • Health spending per person: 194 US$ per person (2023). World: 1,317 US$ per person (2023). 8th highest of the 15 countries we cover in APAC.[1]
  • Doctors: 0.79 per 1,000 people (2021). World: 1.86 per 1,000 people (2022). 9th highest of the 15 countries we cover in APAC.[2]
  • People aged 65 and over: 5.7% of people (2025). World: 10.4% of people (2025). 14th highest of the 16 countries we cover in APAC.[3]

[1] World Bank Open Data, Health spending per person (US$ per person). Retrieved 17 Nov 2026.

[2] World Bank Open Data, Doctors (per 1,000 people). Retrieved 18 Nov 2026.

[3] World Bank Open Data, People aged 65 and over (% of people). Retrieved 18 Nov 2026.

Free data on this topic

Quick answers

Frequently asked questions

How big is the Non-Hormonal Menopause Drugs market in the Philippines?
Placeholder estimate: about $5.8 Mn in 2025, rising to about $22.6 Mn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Non-Hormonal Menopause Drugs market in the Philippines growing?
Placeholder estimate: about 16.3% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Non-Hormonal Menopause Drugs market report cover?
The report splits the market by drug class (NK3 Receptor Antagonists, SSRIs and SNRIs, Gabapentinoids, Others), indication (Hot Flashes, Sleep Disturbance) and end user (Hospitals, Specialty Clinics, Retail Pharmacies, Online Pharmacies).
Who are the key players in the Non-Hormonal Menopause Drugs market?
Key players include Astellas Pharma Inc., Bayer AG, Pfizer Inc. and Noven Pharmaceuticals.
What is driving the Non-Hormonal Menopause Drugs market?
Greater awareness of women's health needs, more funding for female-focused research, later pregnancies and an ageing female population are driving the non-Hormonal Menopause Drugs market. New products designed around women's biology and digital care are improving access.
Who regulates Non-Hormonal Menopause Drugs in the Philippines?
Drug products need registration with the Food and Drug Administration of the Philippines (FDA). Source: Food and Drug Administration Philippines. Checked 14 Nov 2026.
How is healthcare paid for in the Philippines?
PhilHealth is the national health insurer, and the Universal Health Care Act of 2019 makes every Filipino a member. Source: PhilHealth. Checked 14 Nov 2026.
How much research is published on Non-Hormonal Menopause Drugs?
PubMed lists 13 papers on Non-Hormonal Menopause Drugs added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.
Back to Catalogue

Related Pharmaceuticals reports in Philippines

See all

Related on women's health

See the topic